---
title: "PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294264310.md"
description: "PharmaCyte Biotech reported a net loss of $19.42 million for FY26, reversing a $30.66 million profit from the prior year, with no revenue generated. Operating expenses rose 56.5% to $6.85 million due to impairment charges, while cash reserves increased to $18.6 million. The company is working to lift an FDA clinical hold on its IND for a pancreatic cancer trial using Cell-in-a-Box technology."
datetime: "2026-07-29T21:20:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294264310.md)
  - [en](https://longbridge.com/en/news/294264310.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294264310.md)
---

# PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenue

-   PharmaCyte Biotech posted a net loss of USD 19.42 million for fiscal 2026, swinging from net income of USD 30.66 million a year earlier. \* Other income fell to a net expense of USD 12.57 million from net income of USD 35.03 million, driven by fair-value losses on QCLS and warrant positions. \* Operating expenses climbed 56.5% to USD 6.85 million, including a USD 1.55 million impairment charge; R&D spending edged down to USD 391,301. \* Cash and cash equivalents rose to USD 18.6 million, while working capital increased to USD 36.6 million. \* The company continues work to lift the FDA clinical hold on its IND for a planned locally advanced pancreatic cancer trial using Cell-in-a-Box encapsulated live cells. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005836), on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PMCB.US](https://longbridge.com/en/quote/PMCB.US.md)

## Related News & Research

- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Granite-Integral co-leads $34 million Series D financing in Craif](https://longbridge.com/en/news/296226716.md)
- [Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | SLXN Stock News](https://longbridge.com/en/news/295937580.md)
- [ExpreS2ion says ES2B-C001 Phase I trial shows anti-HER2 antibody response in 12 of 13 patients, no dose-limiting toxicities](https://longbridge.com/en/news/296452642.md)
- [RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers](https://longbridge.com/en/news/296039942.md)